Background: Obesity prevalence is growing in our population. Twin studies have estimated the heritability of dietary intakes to about 30%. The objective of this study was to verify whether polymorphisms in genes involved in fatty acid metabolism are associated with dietary fat intakes. Methods: Seven hundred participants were recruited. A validated food frequency questionnaire was used to assess dietary intakes. PCR-RFLP and TAQMAN methodology were used to genotype PPAR α Leu162Val, PPAR γ Pro12Ala, PPAR δ –87T>C, PPARGC1 α Gly482Ser, FASN Val1483Ile and SREBF1 c.*619C>G. Statistical analyses were executed with SAS statistical package. Results: Carriers of the Ala12 allele of PPAR γ Pro12Ala polymorphism had higher intakes of total fat (p = 0.04). For FASN Val1483Ile polymorphism, significant gene-sex interaction effects were found for total fat and saturated fat intakes (p = 0.02 and p = 0.002, respectively). No significant difference in fat intakes was observed for PPAR α Leu162Val, PPAR δ –87T>C, PPARGC1 α Gly482Ser and SREBF1 c.*619C>G polymorphisms. Conclusions: Polymorphisms in PPAR γ and FASN seem to be associated with dietary fat intakes. Genetic variants are important to take into account when studying dietary intakes.

1.
Statistique Canada: L’obésité chez les adultes au Canada. 2008. http://www.statcan.gc.ca/pub/82-620-m/2005001/article/adults-adultes/8060-fra.htm#1.
2.
Wyatt SB, Winters KP, Dubbert PM: Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006;331:166–174.
3.
Bell CG, Walley AJ, Froguel P: The genetics of human obesity. Nat Rev Genet 2005;6:221–234.
4.
Melanson EL, Astrup A, Donahoo WT: The relationship between dietary fat and fatty acid intake and body weight, diabetes, and the metabolic syndrome. Ann Nutr Metab 2009;55:229–243.
5.
Elmadfa I, Kornsteiner M: Fats and fatty acid requirements for adults. Ann Nutr Metab 2009;55:56–75.
6.
Choquette AC, Lemieux S, Tremblay A, Chagnon YC, Bouchard C, Vohl MC, et al: Evidence of a quantitative trait locus for energy and macronutrient intakes on chromosome 3q27.3: the Quebec Family Study. Am J Clin Nutr 2008;88:1142–1148.
7.
Hasselbalch AL, Heitmann BL, Kyvik KO, Sorensen TI: Studies of twins indicate that genetics influence dietary intake. J Nutr 2008;138:2406–2412.
8.
Hur YM, Bouchard TJ Jr, Eckert E: Genetic and environmental influences on self-reported diet: a reared-apart twin study. Physiol Behav 1998;64:629–636.
9.
van BM, van Nieuwenhoven FA: PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets 2010;14:1029–1045.
10.
Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004;10:355–361.
11.
Hihi AK, Michalik L, Wahli W: PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 2002;59:790–798.
12.
Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, et al: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397–403.
13.
Fernandez-Alvarez A, Alvarez MS, Gonzalez R, Cucarella C, Muntane J, Casado M: Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 2011;286:21466–21477.
14.
Duval C, Muller M, Kersten S: PPARalpha and dyslipidemia. Biochim Biophys Acta 2007;1771:961–971.
15.
Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, Campolongo P, et al: The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 2008;8:281–288.
16.
Fu J, DiPatrizio NV, Guijarro A, Schwartz GJ, Li X, Gaetani S, et al: Sympathetic activity controls fat-induced oleoylethanolamide signaling in small intestine. J Neurosci 2011;31:5730–5736.
17.
Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, et al: Molecular scanning of the human PPARα gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000;41:945–952.
18.
Rudkowska I, Caron-Dorval D, Verreault M, Couture P, Deshaies Y, Barbier O, et al: PPARalpha L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity. Mol Nutr Food Res 2010;54:543–550.
19.
Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, et al: Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004;49:482–489.
20.
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:1224–1234.
21.
Masugi J, Tamori Y, Mori H, Koike T, Kasuga M: Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178–182.
22.
Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284–287.
23.
Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G, et al: Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 2011;17:618–622.
24.
Perreault M, Will S, Panza D, Gareski T, Harding K, Kubasiak D, et al: Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice. Diabetes Obes Metab 2010;12:234–245.
25.
Barish GD, Narkar VA, Evans RM: PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590–597.
26.
Harrington WW, Britt S, Wilson G, Milliken O, Binz G, Lobe C, et al: The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice. PPAR Res 2007;2007:97125.
27.
Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E: Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003;23:637–643.
28.
Puigserver P, Spiegelman BM: Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78–90.
29.
Esterbauer H, Oberkofler H, Krempler F, Patsch W: Human peroxisome proliferator activated receptor gamma coactivator 1 (PPARGC1) gene: cDNA sequence, genomic organization, chromosomal localization, and tissue expression. Genomics 1999;62:98–102.
30.
Miura S, Kai Y, Kamei Y, Ezaki O: Isoform-specific increases in murine skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) mRNA in response to beta2-adrenergic receptor activation and exercise. Endocrinology 2008;149:4527–4533.
31.
Ma D, Li S, Lucas EK, Cowell RM, Lin JD: Neuronal inactivation of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) protects mice from diet-induced obesity and leads to degenerative lesions. J Biol Chem 2010;285:39087–39095.
32.
Yang Y, Mo X, Chen S, Lu X, Gu D: Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 2011;27:177–184.
33.
Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, Hedegger M, Wolfsgruber P, et al: Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes 2002;51:1281–1286.
34.
Ridderstrale M, Johansson LE, Rastam L, Lindblad U: Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men. Diabetologia 2006;49:496–500.
35.
Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, et al: Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 2006;49:501–505.
36.
Stumvoll M, Fritsche A, t’Hart LM, Machann J, Thamer C, Tschritter O, et al: The Gly482Ser variant in the peroxisome proliferator-activated receptor gamma coactivator-1 is not associated with diabetes-related traits in non-diabetic German and Dutch populations. Exp Clin Endocrinol Diabetes 2004;112:253–257.
37.
Chen S, Yan W, Huang J, Yang W, Gu D: Peroxisome proliferator-activated receptor-gamma coactivator-1alpha polymorphism is not associated with essential hypertension and type 2 diabetes mellitus in Chinese population. Hypertens Res 2004;27:813–820.
38.
Nitz I, Ewert A, Klapper M, Doring F: Analysis of PGC-1alpha variants Gly482Ser and Thr612Met concerning their PPARgamma2-coactivation function. Biochem Biophys Res Commun 2007;353:481–486.
39.
Choi YS, Hong JM, Lim S, Ko KS, Pak YK: Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem Biophys Res Commun 2006;344:708–712.
40.
Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, et al: Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999;98:115–124.
41.
Semenkovich CF: Regulation of fatty acid synthase (FAS). Prog Lipid Res 1997;36:43–53.
42.
Franck N, Gummesson A, Jernas M, Glad C, Svensson PA, Guillot G, et al: Identification of adipocyte genes regulated by caloric intake. J Clin Endocrinol Metab 2011;96:E413–E418.
43.
Berndt J, Kovacs P, Ruschke K, Kloting N, Fasshauer M, Schon MR, et al: Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes. Diabetologia 2007;50:1472–1480.
44.
Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, et al: Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000;288:2379–2381.
45.
Tu Y, Thupari JN, Kim EK, Pinn ML, Moran TH, Ronnett GV, et al: C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure. Endocrinology 2005;146:486–493.
46.
Kovacs P, Harper I, Hanson RL, Infante AM, Bogardus C, Tataranni PA, et al: A novel missense substitution (Val1483Ile) in the fatty acid synthase gene (FAS) is associated with percentage of body fat and substrate oxidation rates in nondiabetic Pima Indians. Diabetes 2004;53:1915–1919.
47.
Schleinitz D, Kloting N, Korner A, Berndt J, Reichenbacher M, Tonjes A, et al: Effect of genetic variation in the human fatty acid synthase gene (FASN) on obesity and fat depot-specific mRNA expression. Obesity (Silver Spring) 2010;18:1218–1225.
48.
Moreno-Navarrete JM, Botas P, Valdes S, Ortega FJ, Delgado E, Vazquez-Martin A, et al: Val1483Ile in FASN gene is linked to central obesity and insulin sensitivity in adult white men. Obesity (Silver Spring) 2009;17:1755–1761.
49.
Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125–1131.
50.
Shimomura I, Shimano H, Horton JD, Goldstein JL, Brown MS: Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 1997;99:838–845.
51.
Shimano H: SREBPs: physiology and pathophysiology of the SREBP family. FEBS J 2009;276:616–621.
52.
Shimano H: Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm 2002;65:167–194.
53.
Grarup N, Stender-Petersen KL, Andersson EA, Jorgensen T, Borch-Johnsen K, Sandbaek A, et al: Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects. Diabetes 2008;57:1136–1142.
54.
Paradis AM, Godin G, Perusse L, Vohl MC: Associations between dietary patterns and obesity phenotypes. Int J Obes (Lond) 2009;33:1419–1426.
55.
Goulet J, Nadeau G, Lapointe A, Lamarche B, Lemieux S: Validity and reproducibility of an interviewer-administered food frequency questionnaire for healthy French-Canadian men and women. Nutr J 2004;3:13.
56.
Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997;241:270–274.
57.
Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999;14:143–149.
58.
Robitaille J, Despres JP, Perusse L, Vohl MC: The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 2003;63:109–116.
59.
Robitaille J, Gaudet D, Perusse L, Vohl MC: Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta –87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 2007;31:411–417.
60.
Felder TK, Oberkofler H, Weitgasser R, Mackevics V, Krempler F, Paulweber B, et al: The SREBF-1 locus is associated with type 2 diabetes and plasma adiponectin levels in a middle-aged Austrian population. Int J Obes (Lond) 2007;31:1099–1103.
61.
Bouchard-Mercier A, Godin G, Lamarche B, Perusse L, Vohl MC: Effects of peroxisome proliferator-activated receptors, dietary fat intakes and gene-diet interactions on peak particle diameters of low-density lipoproteins. J Nutrigenet Nutrigenomics 2011;4:36–48.
62.
Kallen CB, Lazar MA: Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 1996;93:5793–5796.
63.
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, et al: Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250–252.
64.
Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ: A role for central nervous system PPAR-gamma in the regulation of energy balance. Nat Med 2011;17:623–626.
65.
Chen K, Li F, Li J, Cai H, Strom S, Bisello A, et al: Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med 2006;12:425–432.
66.
Evans D, Mann WA, de HJ, Michel U, Wendt D, Kortner B, et al: Variation in the gene for human peroxisome proliferator activated receptor gamma (PPARgamma) does not play a major role in the development of morbid obesity. Int J Obes Relat Metab Disord 2000;24:647–651.
67.
Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Amin R: Impact of the Pro12Ala Polymorphism of the PPAR-Gamma 2 Gene on Metabolic and Clinical Characteristics in the Palestinian Type 2 Diabetic Patients. PPAR Res 2009;2009:874126.
68.
Ahluwalia M, Evans M, Morris K, Currie C, Davies S, Rees A, et al: The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naive patients with type 2 diabetes. Diabetes Obes Metab 2002;4:376–378.
69.
Anderson AL, Harris TB, Houston DK, Tylavsky FA, Lee JS, Sellmeyer DE, et al: Relationships of dietary patterns with body composition in older adults differ by gender and PPAR-gamma Pro12Ala genotype. Eur J Nutr 2010;49:385–394.
70.
Adamo KB, Dent R, Langefeld CD, Cox M, Williams K, Carrick KM, et al: Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response. Obesity (Silver Spring) 2007;15:1068–1075.
71.
Memisoglu A, Hu FB, Hankinson SE, Manson JE, De V, I, Willett WC, et al: Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003;12:2923–2929.
72.
Luan J, Browne PO, Harding AH, Halsall DJ, O’Rahilly S, Chatterjee VK, et al: Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 2001;50:686–689.
73.
Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, et al: The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 2007;50:2451–2460.
74.
Vaccaro O, Lapice E, Monticelli A, Giacchetti M, Castaldo I, Galasso R, et al: Pro12Ala polymorphism of the PPARgamma2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients. Diabetes Care 2007;30:1156–1161.
75.
Lagou V, Scott RA, Manios Y, Chen TL, Wang G, Grammatikaki E, et al: Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS Study. Obesity (Silver Spring) 2008;16:913–918.
76.
Dedoussis GV, Manios Y, Kourlaba G, Kanoni S, Lagou V, Butler J, et al: An age-dependent diet-modified effect of the PPARgamma Pro12Ala polymorphism in children. Metabolism 2011;60:467–473.
77.
Kim EK, Miller I, Landree LE, Borisy-Rudin FF, Brown P, Tihan T, et al: Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. Am J Physiol Endocrinol Metab 2002;283:E867–E879.
78.
Arsenijevic D, de BF, Plamondon J, Paradis E, Vallet P, Richard D, et al: Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J Cereb Blood Flow Metab 2006;26:433–445.
79.
Jguirim-Souissi I, Jelassi A, Hrira Y, Najah M, Slimani A, Addad F, et al: +294T/C polymorphism in the PPAR-delta gene is associated with risk of coronary artery disease in normolipidemic Tunisians. Genet Mol Res 2010;9:1326–1333.
80.
Aberle J, Hopfer I, Beil FU, Seedorf U: Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 2006;3:108–111.
81.
Eberle D, Clement K, Meyre D, Sahbatou M, Vaxillaire M, Le GA, et al: SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 2004;53:2153–2157.
82.
Black AE, Goldberg GR, Jebb SA, Livingstone MB, Cole TJ, Prentice AM: Critical evaluation of energy intake data using fundamental principles of energy physiology: 2. Evaluating the results of published surveys. Eur J Clin Nutr 1991;45:583–599.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.